Page 22 - AN-3-1

Advanced Neurology PSD-95 in neurodevelopmental disorders

subtypes and their modulators with therapeutic potentials. the acute antidepressant-like activity of escitalopram:
J Clin Med Res. 2009;1(2):72-80. Involvement of the noradrenergic system. Exp Brain Res.
2013;226:285-295.
doi: 10.4021/jocmr2009.05.1237
doi: 10.1007/s00221-013-3434-3
78. Rapport MM, Green AA, Page IH. Serum vasoconstrictor
(serotonin): IV. Isolation and characterization. J Bio Chem. 89. Siepmann T, Kepplinger J, Zerna C, et al. The effects of
1948;176(3):1243-1251. pretreatment versus de novo treatment with selective
serotonin reuptake inhibitors on short-term outcome
79. Harrington RA, Lee LC, Crum RM, Zimmerman AW, Hertz‐
Picciotto I. Serotonin hypothesis of autism: Implications for after acute ischemic stroke. J Stroke Cerebrovasc Dis.
selective serotonin reuptake inhibitor use during pregnancy. 2015;24(8):1886-1892.
Autism Res. 2013;6(3):149-168. doi: 10.1016/j.jstrokecerebrovasdis.2015.04.033
doi: 10.1002/aur.1288 90. Aguiar RP, Soares LM, Meyer E, et al. Activation of 5-HT1A
postsynaptic receptors by NLX-101 results in functional
80. Lacivita E, Perrone R, Margari L, Leopoldo M. Targets for recovery and an increase in neuroplasticity in mice with
drug therapy for autism spectrum disorder: Challenges and brain ischemia. Prog Neuropsychopharmacol Biol Psychiatry.
future directions. J Med Chem. 2017;60(22):9114-9141.
2020;99:109832.
doi: 10.1021/acs.jmedchem.7b00965
doi: 10.1016/j.pnpbp.2019.109832
81. Shi J, Landry M, Carrasco GA, Battaglia G, Muma NA.
Sustained treatment with a 5-HT2A receptor agonist causes 91. Blanpied TA, Kerr JM, Ehlers MD. Structural plasticity with
functional desensitization and reductions in agonist-labeled preserved topology in the postsynaptic protein network.
5-HT2A receptors despite increases in receptor protein Proc Natl Acad Sci U S A. 2008;105(34):12587-12592.
levels in rats. Neuropharmacology. 2008;55(5):687-692. doi: 10.1073/pnas.0711669105
doi: 10.1016/j.neuropharm.2008.06.001 92. Bastianetto S, Danik M, Mennicken F, Williams S, Quirion R.
Prototypical antipsychotic drugs protect hippocampal
82. de la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, neuronal cultures against cell death induced by growth
González-Maeso J. Tolerance and cross-tolerance among medium deprivation. BMC Neurosci. 2006;7:28.
psychedelic and nonpsychedelic 5-HT2A receptor agonists
in mice. ACS Chem Neurosci. 2022;13(16):2436-2448. doi: 10.1186/1471-2202-7-28
doi: 10.1021/acschemneuro.2c00170 93. Seo MK, Hien LT, Park MK, et al. AMPA receptor-
mTORC1 signaling activation is required for neuroplastic
83. Gray JA, Roth BL. Paradoxical trafficking and regulation of
5-HT2A receptors by agonists and antagonists. Brain Res. effects of LY341495 in rat hippocampal neurons. Sci
Rep. 2020;10(1):993.
2001;56(5):441-451.
doi: 10.1038/s41598-020-58017-3
doi: 10.1016/s0361-9230(01)00623-2
94. Kobayashi M, Nagata S, Kita Y, et al. Expression of
84. Abbas AI, Yadav PN, Yao WD, et al. PSD-95 is essential a constitutively active phosphatidylinositol 3-kinase
for hallucinogen and atypical antipsychotic drug actions at induces process formation in rat PC12 cells: Use
serotonin receptors. J Neurosci. 2009;29(22):7124-7136.
of Cre/loxP recombination system. J Biol Chem.
doi: 10.1523/JNEUROSCI.1090-09.2009 1997;272(26):16089-16092.
85. Celada P, Puig MV, Amargós-Bosch M, Adell A, Artigas F. doi: 10.1074/jbc.272.26.16089
The therapeutic role of 5-HT1A and 5-HT2A receptors in 95. Reinés A, Cereseto M, Ferrero A, Sifonios L, Podestá MF,
depression. J Psychiatry Neurosci. 2004;29(4):252-265.
Wikinski S. Maintenance treatment with fluoxetine is
86. Yamauchi M, Miyara T, Matsushima T, Imanishi T. necessary to sustain normal levels of synaptic markers
Desensitization of 5-HT2A receptor function by chronic in an experimental model of depression: Correlation
administration of selective serotonin reuptake inhibitors. with behavioral response. Neuropsychopharmacology.
Brain Res. 2006;1067(1):164-169. 2008;33(8):1896-1908.
doi: 10.1016/j.brainres.2005.10.075 doi: 10.1038/sj.npp.1301596
87. Sawyer EK, Mun J, Nye JA, et al. Neurobiological changes 96. O’Leary OF, Wu X, Castren E. Chronic fluoxetine
mediating the effects of chronic fluoxetine on cocaine use. treatment increases expression of synaptic proteins in the
Neuropsychopharmacology. 2012;37(8):1816-1824. hippocampus of the ovariectomized rat: Role of BDNF
signalling. Psychoneuroendocrinology. 2009;34(3):367-381.
doi: 10.1038/npp.2012.29
doi: 10.1016/j.psyneuen.2008.09.015
88. Quesseveur G, Reperant C, David D, Gardier A, Sanchez C,
Guiard B. 5-HT 2A receptor inactivation potentiates 97. Liu YM, Hu CY, Shen JD, Wu SH, Li YC, Yi LT. Elevation

Volume 3 Issue 1 (2024) 16 https://doi.org/10.36922/an.2095